Evotec SE ADR (EVO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Evotec SE ADR (EVO) has a cash flow conversion efficiency ratio of -0.003x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.18 Million) by net assets ($700.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Evotec SE ADR's balance sheet to measure how much of total assets are equity-financed.
Evotec SE ADR - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how Evotec SE ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check EVO cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Evotec SE ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Evotec SE ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Eos Energy Enterprises Inc
NASDAQ:EOSE
|
0.057x |
|
Jiangsu Hengshun Vinegar-Industry Co Ltd
SHG:600305
|
0.024x |
|
ABOUT YOU Holding AG
F:YOU
|
-0.403x |
|
SANOFI CONS HEALTHC IND L
NSE:SANOFICONR
|
0.409x |
|
Shenzhen Hello Tech Energy Co. Ltd. A
SHE:301327
|
N/A |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
0.016x |
|
Acbel Polytech Inc
TW:6282
|
0.013x |
|
Red Cat Holdings Inc
NASDAQ:RCAT
|
-0.134x |
Annual Cash Flow Conversion Efficiency for Evotec SE ADR (2003–2025)
The table below shows the annual cash flow conversion efficiency of Evotec SE ADR from 2003 to 2025. For the full company profile with market capitalisation and key ratios, see EVO market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $813.36 Million | $-9.06 Million | -0.011x | -158.26% |
| 2024-12-31 | $952.52 Million | $18.22 Million | 0.019x | -36.90% |
| 2023-12-31 | $1.12 Billion | $33.95 Million | 0.030x | -82.51% |
| 2022-12-31 | $1.19 Billion | $205.81 Million | 0.173x | +95.39% |
| 2021-12-31 | $1.38 Billion | $122.24 Million | 0.089x | +75.86% |
| 2020-12-31 | $886.41 Million | $44.72 Million | 0.050x | -36.01% |
| 2019-12-31 | $535.47 Million | $42.22 Million | 0.079x | -78.56% |
| 2018-12-31 | $424.88 Million | $156.24 Million | 0.368x | +1026.64% |
| 2017-12-31 | $331.75 Million | $10.83 Million | 0.033x | -89.63% |
| 2016-12-31 | $213.94 Million | $67.36 Million | 0.315x | +276.39% |
| 2015-12-31 | $187.09 Million | $15.65 Million | 0.084x | +448.94% |
| 2014-12-31 | $158.38 Million | $-3.80 Million | -0.024x | -157.25% |
| 2013-12-31 | $158.97 Million | $6.66 Million | 0.042x | -46.57% |
| 2012-12-31 | $152.55 Million | $11.96 Million | 0.078x | +13.75% |
| 2011-12-31 | $147.25 Million | $10.15 Million | 0.069x | +916.62% |
| 2010-12-31 | $132.64 Million | $899.00K | 0.007x | +103.46% |
| 2009-12-31 | $111.49 Million | $-21.85 Million | -0.196x | +28.84% |
| 2008-12-31 | $149.86 Million | $-41.28 Million | -0.275x | -48.33% |
| 2007-12-31 | $170.55 Million | $-31.67 Million | -0.186x | -176.14% |
| 2006-12-31 | $137.18 Million | $-9.22 Million | -0.067x | -367.85% |
| 2005-12-31 | $148.67 Million | $-2.14 Million | -0.014x | +95.23% |
| 2004-12-31 | $61.73 Million | $-18.60 Million | -0.301x | +22.58% |
| 2003-12-31 | $36.03 Million | $-14.02 Million | -0.389x | -- |
About Evotec SE ADR
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more